Pear Therapeutics, Inc. Class A Common Stock
PEAR
PEAR was delisted on the 18th of April, 2023.
40 hedge funds and large institutions have $118M invested in Pear Therapeutics, Inc. Class A Common Stock in 2022 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 19 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 5
18% less funds holding
Funds holding: 49 → 40 (-9)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
47% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 19
69% less capital invested
Capital invested by funds: $385M → $118M (-$267M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.37M |
| 2 |
State Street
Boston,
Massachusetts
|
+$912K |
| 3 |
Millennium Management
New York
|
+$827K |
| 4 |
Mirae Asset Global Investments
Seoul,
South Korea
|
+$815K |
| 5 |
JP Morgan Chase
New York
|
+$354K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$983K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$624K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$589K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$301K |
| 5 |
Squarepoint
New York
|
-$257K |
PEAR Hedge Fund Activity: Q2 2022 in Review
40 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Pear Therapeutics, Inc. Class A Common Stock (PEAR) for Q2 2022, worth a combined $118M — down 69% from $385M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of PEAR and 10 opened new positions — a net loss of 9 holders — while 5 trimmed existing stakes and 11 added.
The largest buyer was Deutsche Bank, opening a new position worth an estimated $1.37M. The largest seller was Blue Water Life Science Advisors, exiting entirely with an estimated $983K sold.
- 40 institutional investors held Pear Therapeutics, Inc. Class A Common Stock (PEAR) as of Q2 2022, down from 49 in Q1 2022.
- Funds reported $118M of Pear Therapeutics, Inc. Class A Common Stock stock for Q2 2022, down 69% quarter-over-quarter.
- 10 funds opened new Pear Therapeutics, Inc. Class A Common Stock positions in Q2 2022 and 19 closed out, a net change of -9 holders.
- The largest Pear Therapeutics, Inc. Class A Common Stock buyer in Q2 2022 was Deutsche Bank, an estimated $1.37M added.
- The largest Pear Therapeutics, Inc. Class A Common Stock seller in Q2 2022 was Blue Water Life Science Advisors, an estimated $983K sold.
Based on aggregated 13F filings for Q2 2022.